Free Trial Information
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...structural biology company Syrrx Inc. for $270 million in cash, followed by the acquisition of Paradigm Therapeutics Ltd....
Read More
BioCentury | Apr 14, 2008
Strategy

Global millennium

...capability (see BioCentury, Feb. 14, 2005). Last year, Takeda acquired metabolic, neurology and cancer company Paradigm Therapeutics Ltd....
Read More
BioCentury | Dec 3, 2007
Company News

Sareum board of directors update

...Cambridge, U.K. Business: Supply/Service, Computational chemistry/biology, High throughput screening Appointed: Alastair Riddell, former CEO of Paradigm Therapeutics Ltd. WIR...
Read More
BioCentury | Mar 19, 2007
Company News

Paradigm Thera, Takeda Pharmaceuticals Co. Ltd. deal

...BioVentures advised Paradigm on the deal, which is expected to close in a few weeks. Paradigm Therapeutics Ltd....
Read More
BioCentury | Feb 27, 2006
Company News

Argenta Discovery management update

...Harlow, U.K. Business: Supply/Service Hired: John Montana as CSO and a director, formerly CSO of Paradigm Therapeutics Ltd....
Read More
BioCentury | Jul 4, 2005
Company News

Paradigm Thera, J&J, Takeda deal

...million in milestones for each product under the deal. Paradigm also is eligible for royalties. Paradigm Therapeutics Ltd....
Read More
BioCentury | May 30, 2005
Company News

Paradigm Thera management update

Paradigm Therapeutics Ltd. , Cambridge, U.K. Business: Neurology, Cancer, Metabolic Hired: Alastair Riddell as CEO, currently deputy chairman of the Biotechnology Industry Association WIR Staff cancer Neurology...
Read More
BioCentury | Jan 17, 2005
Company News

Paradigm Thera management update

Paradigm Therapeutics Ltd. , Cambridge, U.K. Business: Neurology, Cancer, Metabolic Transitioned: Mark Carlton to COO from CEO WIR Staff cancer Neurology...
Read More
BioCentury | Jan 17, 2005
Company News

Amedis, Paradigm Thera deal

...will have about £11 million ($21.1 million) in cash. Amedis Pharmaceuticals Ltd. , Cambridge, U.K. Paradigm Therapeutics Ltd....
Read More
BioCentury | May 10, 2004
Company News

Cytomyx Ltd., Paradigm Thera deal

...ion channel cell line production and its drug discovery services. Cytomyx Ltd. , Cambridge, U.K. Paradigm Therapeutics Ltd....
Read More
Items per page:
1 - 10 of 12
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...structural biology company Syrrx Inc. for $270 million in cash, followed by the acquisition of Paradigm Therapeutics Ltd....
Read More
BioCentury | Apr 14, 2008
Strategy

Global millennium

...capability (see BioCentury, Feb. 14, 2005). Last year, Takeda acquired metabolic, neurology and cancer company Paradigm Therapeutics Ltd....
Read More
BioCentury | Dec 3, 2007
Company News

Sareum board of directors update

...Cambridge, U.K. Business: Supply/Service, Computational chemistry/biology, High throughput screening Appointed: Alastair Riddell, former CEO of Paradigm Therapeutics Ltd. WIR...
Read More
BioCentury | Mar 19, 2007
Company News

Paradigm Thera, Takeda Pharmaceuticals Co. Ltd. deal

...BioVentures advised Paradigm on the deal, which is expected to close in a few weeks. Paradigm Therapeutics Ltd....
Read More
BioCentury | Feb 27, 2006
Company News

Argenta Discovery management update

...Harlow, U.K. Business: Supply/Service Hired: John Montana as CSO and a director, formerly CSO of Paradigm Therapeutics Ltd....
Read More
BioCentury | Jul 4, 2005
Company News

Paradigm Thera, J&J, Takeda deal

...million in milestones for each product under the deal. Paradigm also is eligible for royalties. Paradigm Therapeutics Ltd....
Read More
BioCentury | May 30, 2005
Company News

Paradigm Thera management update

Paradigm Therapeutics Ltd. , Cambridge, U.K. Business: Neurology, Cancer, Metabolic Hired: Alastair Riddell as CEO, currently deputy chairman of the Biotechnology Industry Association WIR Staff cancer Neurology...
Read More
BioCentury | Jan 17, 2005
Company News

Paradigm Thera management update

Paradigm Therapeutics Ltd. , Cambridge, U.K. Business: Neurology, Cancer, Metabolic Transitioned: Mark Carlton to COO from CEO WIR Staff cancer Neurology...
Read More
BioCentury | Jan 17, 2005
Company News

Amedis, Paradigm Thera deal

...will have about £11 million ($21.1 million) in cash. Amedis Pharmaceuticals Ltd. , Cambridge, U.K. Paradigm Therapeutics Ltd....
Read More
BioCentury | May 10, 2004
Company News

Cytomyx Ltd., Paradigm Thera deal

...ion channel cell line production and its drug discovery services. Cytomyx Ltd. , Cambridge, U.K. Paradigm Therapeutics Ltd....
Read More
Items per page:
1 - 10 of 12